CStone Pharma-B (02616) surged more than 5%, reaching HK$6.07 by the time of writing, with a trading volume of HK$22.70 million. The increase follows the company's announcement that its RET inhibitor, GAVRETO® (pralsetinib capsules, 100 mg), has been successfully included in the latest National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration. The updated list will take effect on January 1, 2026.

To date, CStone Pharma has secured approvals for four innovative drugs, three of which—developed and registered in China—are now covered under the NRDL. A research report by TF Securities in August highlighted that pralsetinib's inclusion in the NRDL is expected to accelerate its market adoption.

CStone Pharma's preclinical pipeline includes over nine potential candidates, such as multispecific antibodies and ADCs, focusing on first-in-class (FIC) and best-in-class (BIC) research across oncology, autoimmune, and inflammatory diseases. The company's proprietary ADC technology platform, featuring optimized linkers for improved tumor-selective payload release, supports multiple ADC products in its Pipeline 2.0, providing sustained momentum for future growth.